John Tsai
Director/Board Member chez BLUEPRINT MEDICINES CORPORATION
Fortune : 2 M $ au 31/03/2024
Profil
John Tsai is currently the Chief Executive Officer at Forcefield Therapeutics Ltd., Chairman & Managing Director at SwanBio Therapeutics, Inc., Independent Director at Blueprint Medicines Corp., and Executive Partner at Syncona Partners LLP.
He previously worked as the Director at Novartis Institute for Functional Genomics, Inc., Chief Medical Officer & SVP-Global Medical at Amgen, Inc., Head-Clinical Development at Bristol Myers Squibb Co., and Chief Medical Officer & President at Novartis AG.
Dr. Tsai received his undergraduate degree from Washington University in St. Louis and his doctorate from the University of Louisville School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
NOVARTIS AG
0,00% | 31/12/2022 | 13 550 ( 0,00% ) | 1 M $ | 31/03/2024 |
21/06/2023 | 6 500 ( 0,01% ) | 616 590 $ | 31/03/2024 |
Postes actifs de John Tsai
Sociétés | Poste | Début |
---|---|---|
BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 06/01/2023 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
Forcefield Therapeutics Ltd. | Chief Executive Officer | 27/09/2023 |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chairman | 16/10/2023 |
Anciens postes connus de John Tsai
Sociétés | Poste | Fin |
---|---|---|
NOVARTIS AG | Chief Tech/Sci/R&D Officer | 15/05/2022 |
AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/01/2018 |
BRISTOL-MYERS SQUIBB COMPANY | Private Equity Investor | 01/01/2012 |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - |
Formation de John Tsai
Washington University in St. Louis | Undergraduate Degree |
University of Louisville School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
AMGEN INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
NOVARTIS AG | Health Technology |
BLUEPRINT MEDICINES CORPORATION | Health Technology |
Entreprise privées | 4 |
---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
Forcefield Therapeutics Ltd. |